TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01802333

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study: NCT01310478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human endostatin (Endostat)
Description: mFOLFOX6:Oxaliplatin 85 mg/m2 d1 Leucovorin 400 mg/m2 d1+5-FU 400 mg/m2 bolus d1+5-FU 2.4 CIV 46h Endostar 7.5mg/m2/d～45mg/m2/d continous intravenous d4～d14
Study: NCT04771325

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Support from a trained companion
Description: Birth companions trained on how to effectively support women during labor

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support from a trained companion
Description: Birth companions trained on how to effectively support women during labor
Study: NCT03908476

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Burst-capable SCS system
Description: Subjects will be given Burst stimulation using a market-released Abbott SCS system. Burst stimulation may be achieved through surgical or non-surgical means.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DRG Stimulator
Description: Subjects will be implanted with a market-released Abbott DRG stimulation system.
Study: NCT00652080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: API 31510
Description: Topical Cream; 3% active; AM \& PM application
Study: NCT01802333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Given IV
Study: NCT04124003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-963272
Description: Specified dose on specified days
Study: NCT01660620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betaxolol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: topical betaxolol
Description: given topically
Study: NCT03543943

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Individualized treatment of Acute Achilles tendon rupture.
Description: The most proximal border of the calcaneus and the most distal point of the musculotendinous junction of the medial gastrocnemius muscle is identified and marked on the skin. These two points on the un-injured leg defines the original length of the total Achilles tendon \[1\]. The difference in length between the injure and the un-injured leg determines elongation for the ruptured Achilles tendon. The relative elongation of the ruptured tendon together with overlap of the tendon ends on the cross-sectional area determines the treatment for the patients receiving individualized treatment: 1) patients with 0-6% elongation of the tendon and a minimum of 25% tendon are treated non-operatively 2) patients with 7% elongation or more or less than 25% tendon overlap are treated operatively.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-operative treatment
Description: Circulated cast below the knee in maximal, unforced plantar flexion over the ankel.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Operative treatment
Description: Open surgery with suture of the ruptured achilles tendon prior to circulated cast below the knee in maximal, unforced plantar flexion over the ankel.
Study: NCT01659099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GA101
Description: in GA-ACBVP or in GA-CHOP 1000 mg on D1 and D8 (D8 in cycle 1 and 2)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: in R-ACBVP or in R-CHOP 375 mg/m² on D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: in ACBVP : 75 mg/m² on D1 in CHOP : 50 mg/m² on D1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: in ACBVP : 75 mg/m² on D1 in CHOP : 50 mg/m² on D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: in ACBVP : 1200 mg/m² on D1 in CHOP : 750 mg/m² on D1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: in ACBVP : 1200 mg/m² on D1 in CHOP : 750 mg/m² on D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: in ACBVP : 60 mg/m² from D1 to D5 in CHOP : 40 mg/m² from D1 to D5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: in ACBVP : 60 mg/m² from D1 to D5 in CHOP : 40 mg/m² from D1 to D5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: in ACBVP 10 mg from D1 to D5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bleomycin
Description: in ACBVP 10 mg from D1 to D5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vindesin
Description: in ACBVP 2 mg/m² from D1 to D5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vindesin
Description: in ACBVP 2 mg/m² from D1 to D5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: in CHOP 1,4 mg/m² on D1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: in CHOP 1,4 mg/m² on D1
Study: NCT03761069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTC299
Description: PTC299 will be administered per the treatment arm description
Study: NCT01798030

Intervention type: OTHER
Intervention: Vitamin D
Description: N/A, frozen specimen study
Study: NCT01802333

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00002704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesna

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study: NCT05087719

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: experimental group
Description: patients will receive the hot pack initially for 15 minutes .Then for proprioception training of graphesthesia for 15 mints,stereognosis will be of 15 minutes. For motor training patients will practice 15 mints motor tasks

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment
Description: patients will receive the baseline treatment of hot pack for 15 minutes. The patients in this group will get muscle strengthening exercise of the hand, Range of motion, and stretching of the hand muscles, 3 sets of 8 repetitions were given to the patient, gap of 2 minutes will be given between regimes. For 20 minutes this session will be given to patient by the therapist.
Study: NCT06066073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lavender Oil
Description: Twenty drops of lavender oil was added the distal water which fill the vaporizer which were placed in the waiting room. The patients inhaled the vapors of the lavender oil 20 minutes before starting the dental procedures
Study: NCT00002704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET electron therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET photon therapy
Study: NCT02927470

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham TMS condition
Description: A sham TMS coil will be used to measure baseline performance on the working memory task. The sham coil looks and sounds just like the real coil, but produces a negligible magnetic field. Following the 40 seconds of sham TBS, the subject will perform the working memory task for 45 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OffLine TMS Condition
Description: A total of 200 trains will be delivered successively in 40 s, totaling 600 pulses. The pulses will be delivered at 80% of motor thresholds. A sham TMS coil will be used to measure baseline performance on the working memory task. The sham coil looks and sounds just like the real coil, but produces a negligible magnetic field. Following the 40 seconds of TBS, or sham TBS, the subject will perform the working memory task for 45 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Online TMS condition
Description: A single train of pulses (3 pulses at 50Hz, duration 40ms) will be delivered once during a particular time epoch on each trial, followed by a minimum of 6 seconds of no stimulation. No more than 600 pulses will be applied in a single session. Similar to the offline TMS condition, a sham TMS coil will be used to measure baseline performance on the working memory task. In each session (frontal, sham) subjects will perform the working memory task for 45 minutes.
Study: NCT06486870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadotropin
Description: Human menopausal gonadotrophin (hMG) is given starting on cycle day three in a dose of 75 IU alternate days. The aim of treatment is to achieve mono-ovulation. Monitoring of treatment is achieved by serial transvaginal ultrasound scanning every other day starting from cycle day nine. Size and number of follicles is recorded in patients follow up sheets. The dose of hMG is reviewed around stimulation day 10 and if follicular development is unsatisfactory, the dose is increased to 75 IU daily .If a good response is not achieved day16 ; the cycle is cancelled. A new cycle is commenced with a higher starting dose of hMG (75 IU per day). When one follicle reached a size of \> =18 mm a single dose of 10,000 IU human chorionic gonadotrophin (hCG, Pregnyl, Epifasi, Choriomon) is given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 5 mg LE oral tablets are administered on the fifth day of menses and then every day for 5 days. Treatment is repeated for up to six cycles

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic ovarian drilling
Description: Laparoscopic ovarian drilling will be done according to the following:~Electrocautery using a mixed current in monopolar electrosurgical needle will be into introduced through the ovarian ipsilateral parts and applied up to 4 point cauterisation of the ovarian capsule, each for 4 second, at 40 W and for a diameter of 3mm and a depth of 4 mm in the antimesentric surface . (Amer et al 2003, Sawant S et al 2019) ,the procedure will be applied for one ovary .~The patient under the study will be followed up to six months of continuous marital life after the procedure
Study: NCT01344213

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin with celecoxib
Description: Oral single-dose of pregabalin (150 mg) and celecoxib (400 mg) (PC) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral single dose of placebo 2 capsules 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg
Study: NCT02046213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2006
Description: Single oral 10mg dose of 100 uCi \[14C\]E2006
Study: NCT02068391

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching Program
Description: The 'Stretching Program' will teach stretching for the upper and lower limbs, and the trunk, as well as breathing exercises for relaxation. Supervised group activities will be performed once per week (45 minutes) and self-directed stretching will be encouraged 4 days per week and monitored by an activity journal. The intensity of stretching and number of stretches will be progressed every 2 weeks. Heart rate and perceived exertion will be monitored. The program will last 6 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: The 'Exercise Program' will prescribe specific aerobic exercise to the participants. Supervised group exercise will be performed once per week (60 minutes) and self-directed exercise will be encouraged 4 days per week and monitored by an activity journal. The initial walking prescription will be set at \~1.6 km and an intensity equivalent to the anaerobic threshold and/or 60% of peak oxygen uptake. Progressions will be made every 2 weeks, increasing distance to a maximum of 6.4 km and then increasing to a max intensity of 80% of peak oxygen uptake and/or max duration of 60 minutes. Heart rate and perceived exertion will be monitored. The program will last 6 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Program
Description: The 'Exercise Program' will prescribe specific aerobic exercise to the participants. Supervised group exercise will be performed once per week (60 minutes) and self-directed exercise will be encouraged 4 days per week and monitored by an activity journal. The initial walking prescription will be set at \~1.6 km and an intensity equivalent to the anaerobic threshold and/or 60% of peak oxygen uptake. Progressions will be made every 2 weeks, increasing distance to a maximum of 6.4 km and then increasing to a max intensity of 80% of peak oxygen uptake and/or max duration of 60 minutes. Heart rate and perceived exertion will be monitored. The program will last 6 months.
Study: NCT01362062

Intervention type: DRUG
Intervention: Tocilizumab
Study: NCT03703609

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-yoga
Description: Participants will get a 60 min tele-yoga session biweekly led by a certified medical yoga instructor via live videoconference link on the participants tablet. Each participant will perform a total of 20-24 yoga instructor-led sessions over a 12-week period. A session will contain 10 min breathing exercises, 40 min of yoga and 10 min relaxation/meditation. Before and at the end of each session, participants can discuss their experiences or ask questions to the instructor online. The tablet also includes an app with instructions (text, pictures, and sound files) for yoga positions, breathing and meditation. Participants are encouraged to practice yoga at home individually with one goal of one session a day for a minimum of 10 minutes.
Study: NCT03804476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AER-271
Description: AER-271, the test article for this study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control for this study.
Study: NCT03223649

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking Bouts
Description: Six daily 3 hour sessions with prompted 3-minute moderate-intensity walking bouts performed on a treadmill every 30 minutes throughout the 3 hour duration. There will be a total of 6 walking bouts (18 minutes total) each day. Moderate-intensity walking speed and grade will be selected to achieve 80% of the heart rate achieved at the ventilatory threshold as determined during a V02max test.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sedentary
Description: (Control 'intervention') Six daily 3 hour sessions with no physical activity (i.e. subject remains sedentary in seated or recumbent position) throughout the 3 hour duration.
Study: NCT00331058

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bronchoscopsy
Description: Healthy and Asthmatic Volunteers

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Prednisolone
Description: Asthmatic Volunteers
Study: NCT00444639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin (Decapeptyl®)
Description: Two injections of 11.25mg given every 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin (Decapeptyl®)
Description: Two injections of 11.25mg given every 12 weeks
Study: NCT04930133

Intervention type: DRUG
Intervention: Gilotrif
Description: This is non-interventional, multi-center, multi-cohort study based on existing data from EGFR sensitizing mutation-positive NSCLC patients treated with afatinib as the first-line treatment. Enrolled patients will be categorized into four cohorts (cohort A, B, C and D) according to the type of second line treatment with biopsy results before start of second line treatment.

Intervention type: DRUG
Intervention: Gilotrif
Description: This is non-interventional, multi-center, multi-cohort study based on existing data from EGFR sensitizing mutation-positive NSCLC patients treated with afatinib as the first-line treatment. Enrolled patients will be categorized into four cohorts (cohort A, B, C and D) according to the type of second line treatment with biopsy results before start of second line treatment.

Intervention type: DRUG
Intervention: Gilotrif
Description: This is non-interventional, multi-center, multi-cohort study based on existing data from EGFR sensitizing mutation-positive NSCLC patients treated with afatinib as the first-line treatment. Enrolled patients will be categorized into four cohorts (cohort A, B, C and D) according to the type of second line treatment with biopsy results before start of second line treatment.

Intervention type: DRUG
Intervention: Gilotrif
Description: This is non-interventional, multi-center, multi-cohort study based on existing data from EGFR sensitizing mutation-positive NSCLC patients treated with afatinib as the first-line treatment. Enrolled patients will be categorized into four cohorts (cohort A, B, C and D) according to the type of second line treatment with biopsy results before start of second line treatment.
Study: NCT01944163

Intervention type: OTHER
Group type: OTHER
Intervention: Applying a referral model
Description: GP are randomized in clusters either to use or not to use the CaFaSpA referral model. The CaFaSpA referral models consists out of four variables, a positive ASAS IBP questionnaire, a positive family history for SpA, a good reaction to NSAIDs and back pain duration longer than 5 years. If at least two out of four variables are present a referral to the rheumatologist is advised.
Study: NCT00059592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Study: NCT06066073

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Distal Water
Description: The patients inhaled vapors of the distal water in the waiting room 20 minutes before starting dental procedures
Study: NCT04527939

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: three-dimensional endorectal ultrasonography
Description: three-dimensional endorectal ultrasonography

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: three-dimensional endorectal ultrasonography
Description: three-dimensional endorectal ultrasonography
Study: NCT05354193

Intervention type: OTHER
Intervention: vasoplegic syndrome
Description: In all included patients, 3 milliliters of venous blood will be collected before cardiopulmonary bypass, 3 milliliters of venous blood 15 minutes after the reversal of heparin with protamine and a small fragment of aortic tissue. Samples of biological material will be compared between the control and vasoplegic groups for the difference in amount and type of miRNA present.~For the diagnosis of vasospastic syndrome, the following criteria were adopted: mean arterial pressure \< 65 mmHg, cardiac index \< 2.2 L / min / m2, refractory to replacement of at least 1000 milliliters of crystalloid, excluding other causes such as tamponade, bleeding and cardiogenic shock

Intervention type: OTHER
Intervention: vasoplegic syndrome
Description: In all included patients, 3 milliliters of venous blood will be collected before cardiopulmonary bypass, 3 milliliters of venous blood 15 minutes after the reversal of heparin with protamine and a small fragment of aortic tissue. Samples of biological material will be compared between the control and vasoplegic groups for the difference in amount and type of miRNA present.~For the diagnosis of vasospastic syndrome, the following criteria were adopted: mean arterial pressure \< 65 mmHg, cardiac index \< 2.2 L / min / m2, refractory to replacement of at least 1000 milliliters of crystalloid, excluding other causes such as tamponade, bleeding and cardiogenic shock
Study: NCT00931801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atazanavir/raltegravir
Description: Atazanavir/r 300/100mg once daily plus raltegravir 400mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atazanavir/raltegravir
Description: Atazanavir 300mg twice daily plus raltegravir 400mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atazanavir/tenofovir/emtricitabine
Description: Continue baseline regimen of atazanavir/r 300/100mg once daily plus tenofovir and emtricitabine
Study: NCT02479256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen Placebo
Description: Women will receive one tablet of placebo of tamoxifen oral tablets twice daily 12 hours apart from the 3rd day of the menses for 5 days, for only one menstrual cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Women will receive one tablet of tamoxifen oral tablets 10 mg (Tamoxifen®, amriya/Egypt) twice daily 12 hours apart (total dose 20 mg daily) from 3rd day of the menses for 5 days, for only one menstrual cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate placebo
Description: Women will receive one tablet of placebo of clomiphene citrate twice daily 12 hours apart from 3rd day of the menses for 5 days, for only one menstrual cycle.